Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Asthma
Interventions: Placebo MDPI, Albuterol MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Huntington Beach, California • San Diego, California • Denver, Colorado + 24 more

Conditions: Hematologic Neoplasms
Interventions: Panobinostat; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Duarte, California • Augusta, Georgia • Boston, Massachusetts + 1 more

Conditions: Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
Interventions: StimRouter Neuromodulation System; Device
Lead sponsor: Bioness Inc; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 9
States / cities: La Jolla, California • Larkspur, California • Redwood City, California + 6 more

Conditions: Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions: TPI 287 Injection; Drug
Lead sponsor: Cortice Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Spinal Cord Injuries (SCI), Multiple Sclerosis
Interventions: Individualized reduction of falls (iROLL), Stopping Elderly Accidents, Deaths & Injuries (STEADI); Procedure
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: University College, London; Other
Eligibility: 11 Years to 75 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2017
U.S. locations: 6
States / cities: Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more

Conditions: Atopic Dermatitis
Interventions: Placebo, PF-04965842, PF04965842; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more

Conditions: Obstructive Sleep Apnea, Spinal Cord Injuries
Interventions: Mild intermittent hypoxia, Sham protocol, Continuous positive airway pressure (CPAP); Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Detroit, Michigan

Conditions: Progressive Multiple Sclerosis
Interventions: KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU); Biological · Drug
Lead sponsor: Bruce Cree; Other
Eligibility: 25 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Surgical Wound, Trauma-related Wound
Interventions: ConvaFoam; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Winston-Salem, North Carolina

Conditions: Hypertension
Interventions: Revision of congregate meal menus and recipes to align with parameters of DASH eating plan, On-site blood pressure monitoring, Home self blood pressure monitoring, Medical adherence education, Nutrition Education; Behavioral
Lead sponsor: Rockefeller University; Other
Eligibility: 60 Years to 105 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Juvenile Idiopathic Arthritis, JIA
Interventions: adalimumab, Methotrexate; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: rAAV2tYF-GRK1-RPGR; Biological
Lead sponsor: Beacon Therapeutics; Industry
Eligibility: 6 Years to 50 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Durham, North Carolina • Cincinnati, Ohio • Portland, Oregon + 1 more

Conditions: Aortic Valve Disease
Interventions: Aortic Valve Replacement; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Madera, California • Sacramento, California + 6 more

Conditions: Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
Interventions: Brexpiprazole, Treatment as Usual; Drug · Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Augusta, Georgia • Boston, Massachusetts • Worcester, Massachusetts + 1 more

Conditions: Abdomenal Wound Trauma
Interventions: RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Disease, Metabolic Syndrome
Interventions: Canola Oil, High oleic acid canola oil, Western diet oil combination; Other
Lead sponsor: Penn State University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Menopause
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Lallemand Health Solutions; Industry
Eligibility: 40 Years to 59 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more

Conditions: Advanced HER2-positive Breast Cancer
Interventions: AUY922, Trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Brain Disease
Interventions: MultiHance 0.1 mmol/kg, Dotarem, MultiHance 0.05 mmol/kg; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Corvallis, Oregon

Conditions: Age-Related Macular Degeneration
Interventions: Visudyne, Kenalog; Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 50 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Kidney Injury
Interventions: Niyad (nafamostat mesylate), Placebo (0.9% NaCl); Device
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more

Conditions: Diabetes, Type 1
Interventions: Technosphere Insulin, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Search by objective public record fields.

Safety Study of Albuterol Spiromax® in Subjects With Asthma

Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator

StimRouter Registry Clinical Protocol

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Fall Prevention Among People With Spinal Cord Injury and Multiple Sclerosis Who Use Wheelchairs and Scooters

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds

DASH Diet Intervention at Senior Centers

Juvenile Idiopathic Arthritis (JIA) Registry

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

Non-Comparative Study of Open Abdomen That Require the Use of Negative Pressure Wound Therapy (NPWT) for Temporary Abdominal Closure

Canola Oil Multi-center Intervention Trial II

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Crossover Comparison of MultiHance and Dotarem

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis